Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Ratios

Catalyst Pharmaceuticals (CPRX) Shares Repurchased (2016 - 2026)

Catalyst Pharmaceuticals filings provide 6 years of Shares Repurchased readings, the most recent being $14.6 million for Q1 2026.

On a quarterly basis, Shares Repurchased changed N/A to $14.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $14.6 million, a N/A change, with the full-year FY2025 number at $25.3 million, changed N/A from a year prior.
Shares Repurchased hit $14.6 million in Q1 2026 for Catalyst Pharmaceuticals, up from $7000.0 in the prior quarter.
In the past five years, Shares Repurchased ranged from a high of $14.6 million in Q1 2026 to a low of -$7000.0 in Q3 2022.